The latest game-changing product from Fjord Diagnostics Sdn Bhd is the HPV Urine Rapid Antigen Test Kit, boasting the claim of being the world’s first self-collection HPV testing method for the screening of Cervical Cancer Risk, providing real-time test results in 15-30 minutes, eliminating the need for any of the embarrassment or discomfort that may arise from clinician-taken cervical smear and pelvic examination. Since the Covid-19 pandemic, people across the world have become comfortable and familiar with the idea of self-testing kits, and thanks to Fjord Diagnostics, cervical cancer screening can now be checked using similar technology. This easy-to-use testing kit uses a urine sample, the preferred sample collection of choice for women. This test kit employs the use of the Fjord Diagnostics’ proprietary patented SEDIPREP® Sample Preparation Technology in the pre-concentration of collected HPV urine viral load of up to > 40x, transforming the initial collected urine sample into its final HPV viral load concentration that is now suitable for lateral flow assays.
First-void urine samples can serve as game changers in the field of HPV-based cervical cancer screenings, and with Fjord Diagnostics’ HPV Urine Rapid Antigen Test comes the advantage of an easy self-collection of urine sample combined with the eradication of any embarrassment or discomfort from a clinician-taken cervical smear. This testing kit will appeal to those health-conscious women already attending cervical cancer screenings, as well as the under-screened women who are perhaps afraid, embarrassed, or cannot find the time to go.
It is estimated that between 60 and 70% of the female population in the age range of 30-65 had previously been hesitant to visit a clinic for a pelvic examination and cervical smear test, primarily for the reasons of discomfort, embarrassment, or cultural taboo, so this testing kit may cause a shift in how cervical cancer screening is carried out. Having HPV does not necessarily mean that a person will develop cancer, as there are more than 100 types of the HPV virus, yet only 14 of these are associated with cancer. However, early detection not only helps to treat cervical abnormalities and any existing cancer but can act also as a vital preventative measure.
Over time, cervical cancer screening strategies have evolved massively, initially starting out as cytology-based prior to HPV being identified as the cause of cervical cancer, and the subsequent introduction of tests to help detect it. A self-testing kit is the next step in this natural evolution, and Fjord Diagnostics succeeded in its aim to develop a self-collection test that was simple, rapid, and cost-effective. Much like the Covid-19 rapid tests, the pre-concentrated urine specimen is mixed with a fluid before being squeezed onto a test card, with results shown in the form of C and T lines, with one line indicating a negative result, two lines a positive one, and with no line on C invalidating the test.
Each kit includes one individual test card, one urine container, one SEDIPREP® Sample Preparation device for HPV viral load pre-concentration, one extraction tube, one dropper pipette, and one packaging insert complete with instructions. The test should only be used for a qualitive diagnosis and is suitable for detecting cervical pre-cancer and cancer caused by hrHPV. Following on from a positive result, a diagnosis should be confirmed by a physician only after all clinical and laboratory findings have been evaluated fully.
Thanks to Fjord Diagnostics’ SEDIPREP® reverse filtration process technology platform, technological advancement in the field of sample preparation of body fluid for analysis has never been so efficient and effective. The company boasts a recovery yield of up to 100%, standardised preparation, a quick turnaround, and ease of use across its systems, most abundantly clear in “the SEDIPREP® advantage” which comes into play when comparing the company’s SEDIPREP® method with that of the error-prone centrifugation method. With four simple steps, the higher recovery yield of investigative analytes can be garnered, making the SEDIPREP® method the best choice for separating investigative analytes from the liquid sample for analysis purposes.
Ultimately, Fjord Diagnostics has unveiled a revolutionary new self-testing kit that makes testing for a preventable disease like cervical cancer quick, easy, and able to be carried out from the privacy of one’s own home. This innovation is sure to be the first in a long line of self-testing treatments for cancers and other such diseases, and by spotting the signs early through these tests, treatment has the best possible chance of eradicating the illness, allowing life to be lived to the fullest.
For further information, please contact Robin Chin or visit http://fjorddiagnostics.com/index.html
